Articles Tagged With: HIV
-
Location May Affect Patients’ Requests for Sexual Health Testing
A new study that looks at how state-level confidentiality mandates affect human immunodeficiency virus/sexually transmitted infection testing among high school students found that youth were more likely to be tested in states with confidentiality mandates.
-
HIV Prevention and Education Needed for Young, Female Populations in the U.S.
Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is no longer an epidemic in the United States, but some parts of the country and some populations still have high rates of the disease among young women.
-
Measles Testing of Persons with HIV
A Dallas County human immunodeficiency virus clinic review from 2015-2025 found that only 11% of people with HIV had documented measles immunity, with younger patients, white and Hispanic patients, and patients with low CD4 counts more likely to be seronegative.
-
Infectious Disease Updates
Visceral Larva Migrans from Baylisascariasis; Measles Testing of Persons with HIV; Ambulatory Glucose Monitoring a Risk for Bloodborne Pathogens
-
Lenacapavir Injection and Tablets (Yeztugo)
The U.S. Food and Drug Administration has approved lenacapavir, a potent, first-in-class, capsid inhibitor, for reducing the risk of sexually acquired human immunodeficiency virus type 1.
-
Twice-Yearly Subcutaneous Lenacapavir Injection Prevents HIV Infection
Subcutaneous injection of lenacapavir every 26 weeks had 100% efficacy in preventing human immunodeficiency virus (HIV) infection in a high-risk population.
-
A Review of HIV Pre-Exposure Prophylaxis
Human immunodeficiency virus (HIV) pre-exposure prophylaxis is a tool for preventing HIV, especially among high-risk populations. Three medication options are available. Regular screening for HIV and sexually transmitted infections is required, and adherence is crucial for effectiveness. PrEP is underused but increasingly covered by insurance, offering an important preventive option in sexual healthcare.
-
Twice-Yearly Subcutaneous Lenacapavir Injection Prevents HIV Infection
Subcutaneous injection of lenacapavir every 26 weeks had 100% efficacy in preventing human immunodeficiency virus (HIV) infection in a high-risk population.
-
Message Needs to Get Out that PrEP Is Not Only for Cisgender Men
Cisgender women sometimes are left out of the provider-patient conversations when it comes to discussing their risk of human immunodeficiency virus (HIV) infection and how pre-exposure prophylaxis (PrEP) can make them safer, a new paper finds.
-
A Review of HIV Pre-Exposure Prophylaxis
Knowing one’s human immunodeficiency virus (HIV) status can help patients take steps to prevent transmission. Male and female condoms are options for preventing HIV during sexual intercourse. These products are widely available over the counter in retail stores and pharmacies and their use should be encouraged for preventing sexually transmitted infections. Yet, there is another option available, pre-exposure prophylaxis (PrEP), for patients to prevent HIV that many providers have not yet added to their armamentarium. This special feature will review the indications for PrEP, its use, and the medications recommended.